Clinically, the NAFLD group exhibited elevated levels of systolic and diastolic blood pressure, HOMA-IR, waist circumference, triglycerides, ALT, AST, GGT, fasting glucose, CRP, HbA1c, and CAP, along with reduced levels of HDL-C. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.